Dividend Assets Capital LLC Sells 12,825 Shares of Stryker Co. (NYSE:SYK)

Dividend Assets Capital LLC lessened its holdings in Stryker Co. (NYSE:SYK - Free Report) by 44.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,268 shares of the medical technology company's stock after selling 12,825 shares during the period. Dividend Assets Capital LLC's holdings in Stryker were worth $6,056,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. J. W. Coons Advisors LLC lifted its position in shares of Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after purchasing an additional 26 shares during the last quarter. Mascoma Wealth Management LLC increased its position in Stryker by 22.7% in the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after buying an additional 27 shares during the period. Opal Wealth Advisors LLC increased its position in Stryker by 1.6% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after buying an additional 28 shares during the period. Lindbrook Capital LLC lifted its holdings in shares of Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after buying an additional 28 shares during the last quarter. Finally, Capital & Planning LLC boosted its position in shares of Stryker by 3.6% in the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock valued at $304,000 after acquiring an additional 29 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on SYK shares. Sanford C. Bernstein set a $450.00 target price on shares of Stryker in a research note on Monday, May 5th. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research report on Tuesday, March 4th. BTIG Research set a $403.00 target price on shares of Stryker and gave the company a "buy" rating in a research note on Monday, April 14th. Needham & Company LLC restated a "buy" rating and set a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. Finally, Evercore ISI reduced their price objective on Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $427.30.

Stryker Trading Down 1.0%

SYK traded down $4.02 during trading on Wednesday, reaching $381.03. 792,341 shares of the company's stock were exchanged, compared to its average volume of 1,330,630. The company's fifty day moving average price is $370.53 and its 200-day moving average price is $375.91. The firm has a market capitalization of $145.43 billion, a PE ratio of 49.10, a P/E/G ratio of 2.93 and a beta of 0.91. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. During the same period in the previous year, the firm earned $2.50 earnings per share. The firm's quarterly revenue was up 11.9% compared to the same quarter last year. As a group, equities analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker's payout ratio is presently 45.41%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.